Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

459.00 -3.58 (-0.77%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
57 58 Next >
Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
The 7 Best Healthcare Stocks to Invest In for Big Gains in 2024
Invest in the future with healthcare stocks 2024; offering a blend of market stability and cutting-edge medical advancements. 
Via InvestorPlace
This High-Flying Stock Just Got Some Bad News: Should You Sell?
It's just a minor setback for this leading biotech. 
Via The Motley Fool
Vertex Pharmaceuticals (VRTX) Q4 2023 Earnings Call Transcript
VRTX earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Vertex's Next-Gen Cystic Fibrosis Drug Scores Big; Shares Rise On Quarterly Beat
The company also topped fourth-quarter expectations. 
Via Investor's Business Daily
Earnings Preview: Vertex Pharmaceuticals
Via Benzinga
Key Takeaways From Vertex Pharmaceuticals Analyst Ratings
Via Benzinga
Here's My Top Growth Stock to Buy Right Now
There doesn't appear to be a weak link with this great stock. 
Via The Motley Fool
Where Will Vertex Pharmaceuticals Be in 10 Years?
As the adage goes, winners keep winning. 
Via The Motley Fool
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Stocks Fall As Traders Dial Back Rate Cut Bets; Dollar, Treasury Yields Rise: What's Driving Markets Monday?
Wall Street ends week on negative note as traders revise down expectations on Fed rate cuts. Strong economic data and Fed officials' comments push stocks into red, reducing rate cut expectations for... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Vertex Pharmaceuticals Gears Up For Q4 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is expected to release earnings results for its fourth quarter, after the closing bell on Feb. 5, 2024. 
Via Benzinga
Will Jerome Powell Spoil Wall Street's Party? US Stock Futures Slip As Fed Chief Maintains Hawkish Tone Ahead Of More Earnings
As the market pushes higher despite the Federal Reserve's non-committal stance, traders fear a potential drawdown. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Investor Optimism Improves Following Tech Earnings, Jobs Data; S&P 500 Gains For 4th Week
The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index remained in the "Greed" zone on Friday. U.S. stocks closed higher on Friday, with the S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 3
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the week of Jan. 29 through Feb. 2. 
Via Talk Markets
Earnings Scheduled For February 5, 2024
Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is estimated to report quarterly earnings at $0.26 per share on revenue of $43.92 million. 
Via Benzinga
Vertex Pharmaceuticals May Be About to Solve a Common Health Problem. Is the Stock a Buy?
Vertex shares recently reached an all-time high. 
Via The Motley Fool
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
The Dow led the major indexes higher. Big techs diverged on results. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Should Quality Investors Include NASDAQ:VRTX in Their Portfolio?
In this article we'll explore the quality characteristics of VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) 
Via Chartmill
Top Stock Picks 2024: 3 Healthcare Stocks Leading Medical Advancements
Discover how emerging tech is shaping healthcare stocks in 2024. See which companies are outperforming and what it means for your portfolio. 
Via InvestorPlace
Biotech And Medtech Portfolio Notes On A Fed Day
The Fed held rates keeping their future options flexible with no expectations for future cuts. The market did not like it and sold off with the Russell 2000 down 2.45% and the NASDAQ down 2.23% 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Buy Alert: 3 Stocks Sitting in the Sweet Spot
They say timing is everything, so investors will want to take advantage of buying these stocks now instead of waiting. 
Via InvestorPlace
Why Vertex Pharmaceuticals Stock Topped the Market Today
The company reported that it met its primary endpoint in a study for its non-opioid pain drug. 
Via The Motley Fool
Why Is Vertex Pharmaceuticals Stock Sliding Today?
Explore Vertex Pharmaceuticals' Phase 3 results for VX-548, a NaV1.8 inhibitor, demonstrating significant pain relief post-surgery. 
Via Benzinga
Vertex Skids — Its Alternative To Opioids Is 'Not A Game-Changer,' Says Analyst
The company unveiled the results of Phase 3 testing in patients following a tummy tuck or bunion removal. 
Via Investor's Business Daily
Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Is CRISPR Therapeutics a Buy in the New Bull Market?
CRISPR Therapeutics is a specialist in the hot technology of gene editing. 
Via The Motley Fool
AI, Biotech, Energy Sectors Expect M&A Revival For 2024
The AI market, along with energy and biotech, are ripe for M&A following the worst performance in almost a decade for deal-making in 2023. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Magnificent Stocks to Buy and Hold Forever
Many investors will want to consider owning these stocks for a long time. 
Via The Motley Fool
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.